TY - JOUR
AU1 - Mujtaba, Alhasan
AU2 - Taher, Mohammed
AU3 - Hazza, Mazin
AU4 - Al-Rubaye, Hassan
AU5 - Kata, Asaad
AU6 - AbdulWahab, Hamid
AU7 - AbdulBari, AbdulAmeer
AU8 - AlRubay, Hayder
AB - Cardiol Ther (2018) 7:101–106 https://doi.org/10.1007/s40119-018-0112-3 STUDY PROTOCOL The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Study Design and Rationale . . . Alhasan Mujtaba Mohammed A. Taher Mazin A. Hazza . . . Hassan M. Al-Rubaye Asaad H. Kata Hamid AbdulWahab AbdulAmeer AbdulBari Hayder K. AlRubay Received: April 11, 2018 / Published online: May 21, 2018 The Author(s) 2018 center will be allocated in a 1:1 ratio to receive ABSTRACT either spironolactone 200 mg single dose or placebo in addition to their usual Introduction: Patients undergoing coronary premedication. catheterization are at high risk of developing Planned Outcomes: Primary end point will be contrast-induced nephropathy (CIN) acute kid- CIN defined as more than 25% or 0.3 mg/dl ney injury (AKI). Several approaches have been elevation in serum creatinine (S.Cr.) from supposed to limit such an effect but with mixed baseline during the first 2–3 days after the pro- results or non-practical methods. Spironolac- cedure. We hope to identify or answer an tone is supposed to be effective as a nephro- important question regarding CIN in such high- protective agent in animal studies. This study risk patients. will try to measure the effect of 
TI - The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Study Design and Rationale
JF - Cardiology and Therapy
DO - 10.1007/s40119-018-0112-3
DA - 2018-05-21
UR - https://www.deepdyve.com/lp/springer-journals/the-effect-of-spironolactone-on-the-incidence-of-contrast-induced-fVNGoUgl3d
SP - 101
EP - 106
VL - 7
IS - 1
DP - DeepDyve
ER -